Adrish Sen Email & Phone Number

Lead development of statistical and computational pseudo-temporal algorithms for multi-omics data analysis, enhancing patient stratification in clinical trialsSpearhead bioinformatics analysis for ongoing and upcoming Phase 3 and Phase 1 clinical trials, focusing on patient and biomarker identificationDirect planning, execution, and analysis of wet lab projects for pre-clinical NDA-focused studies and drug combination pharmacodynamics in animal modelsDevelop and integrate nextflow and snakemake analysis pipelines using Google cloud compute clusters and LLMs for advanced bioinformatics experimentsFoster productive collaborations with leading computational KOLs to develop novel analytical methods for inferring kinetics from static patient-derived dataLed innovative bioinformatics analysis on endometrial, prostate and breast cancer progression, employing advanced techniques such as trajectory inference and pseudo-temporal reconstruction of tumor transcriptomes. Published findings in Molecular Oncology, NPJ, and Cancers (2024), contributing to the understanding of PAM pathway inhibitors in diverse cancer types .

Minneapolis, Minnesota, United States

Established cloud computational infrastructure (GCP, AWS) to implement scalable and efficient data analysis pipelines, enabling large database and language model integrationLed wet-lab and data analysis for MoA/drug combination identification, supporting advancement to Phase 1b clinical trial in metastatic prostate cancerEnabled strategy formulation, drug MoA identification, assay development, and bioinformatics analysis for multiple cancer types, including prostate, endometrial, and breast cancerDeveloped biomarker discovery (R, python, Jupyter, nextflow) and assay development (FACS, drug MoA GR screens, RT-qPCR, capillary protein electrophoresis) workflowsSupported KOL collaborations and pre-clinical studies for various cancer indications, contributing to ongoing Phase 3 clinical trials

Developed platform for cancer cell vulnerability prioritization, enabling acquisition of a first-in-class oncology drug (awarded FDA breakthrough therapy status for advanced breast cancer)Established wet-lab protocols for high-throughput cell culture and multicolor flow cytometry using cell lines and patient-derived primary cellsCreated robust (QC/QA) experimental procedures for operational scalable use in biomarker panel developmentDeveloped assays and biomarker panels for multi-parameter quantification of drug targets and prognostic markersImproved methods for quantitative high-throughput drug sensitivity analysis (GR metric) and methodology to capture biomarker data from different tissue types

Led laboratory team, maintaining funding, fostering collaborations, and mentoring in a cutting-edge academic environmentDeveloped early approaches to measure and analyze high-dimensional single cell data (microfluidics/transcriptomics, CyTOF) in viral infection modelsEstablished and completed multi-center projects in animal and human models of viral pathogenesis and determinants of species barriersPublished in high-impact journals, submitted grants (RO1, as PI), served as reviewer for multiple journalsDelivered keynote and invited lectures nationally and internationally on virology and immunology research

Ph.D, Virology

Master Of Science (Ms), Environmental Science

Bachelor Of Science (Bs), Environmental Science